- Home
- WINT vs DRMA Comparison
WINT vs DRMA Comparison
Compare WINT & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- DRMA
- Stock Information
- Founded
- WINT 1992
- DRMA 2014
- Country
- WINT United States
- DRMA United States
- Employees
- WINT N/A
- DRMA N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- DRMA Health Care
- Exchange
- WINT Nasdaq
- DRMA Nasdaq
- Market Cap
- WINT 2.0M
- DRMA 2.2M
- IPO Year
- WINT 1995
- DRMA 2021
- Fundamental
- Price
- WINT $0.12
- DRMA $1.26
- Analyst Decision
- WINT Hold
- DRMA Strong Buy
- Analyst Count
- WINT 1
- DRMA 1
- Target Price
- WINT $7.00
- DRMA $6.00
- AVG Volume (30 Days)
- WINT 7.3M
- DRMA 632.3K
- Earning Date
- WINT 11-27-2024
- DRMA 03-20-2025
- Dividend Yield
- WINT N/A
- DRMA N/A
- EPS Growth
- WINT N/A
- DRMA N/A
- EPS
- WINT N/A
- DRMA N/A
- Revenue
- WINT N/A
- DRMA N/A
- Revenue This Year
- WINT N/A
- DRMA N/A
- Revenue Next Year
- WINT N/A
- DRMA N/A
- P/E Ratio
- WINT N/A
- DRMA N/A
- Revenue Growth
- WINT N/A
- DRMA N/A
- 52 Week Low
- WINT $0.11
- DRMA $1.00
- 52 Week High
- WINT $14.75
- DRMA $7.62
- Technical
- Relative Strength Index (RSI)
- WINT 15.60
- DRMA 48.49
- Support Level
- WINT $0.21
- DRMA $1.00
- Resistance Level
- WINT $0.33
- DRMA $1.28
- Average True Range (ATR)
- WINT 0.03
- DRMA 0.16
- MACD
- WINT 0.00
- DRMA -0.01
- Stochastic Oscillator
- WINT 2.15
- DRMA 35.38
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.